Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan 29;60:29268.
doi: 10.3402/fnr.v60.29268. eCollection 2016.

Effect of Long Chain omega-3 Polyunsaturated Fatty Acids on Inflammation and Metabolic Markers in Hypertensive and/or Diabetic Obese Adults: A Randomized Controlled Trial

Free PMC article

Effect of Long Chain omega-3 Polyunsaturated Fatty Acids on Inflammation and Metabolic Markers in Hypertensive and/or Diabetic Obese Adults: A Randomized Controlled Trial

Mohammed S Ellulu et al. Food Nutr Res. .
Free PMC article


Background: Obesity is a degree of excess weight that predisposes people to metabolic syndromes via an inflammatory mechanism. Hypertensive and diabetic people have higher risks of developing systemic inflammation. Long chain omega-3 polyunsaturated fatty acids (LC ω-3 PUFAs) can reduce the cardiovascular events and help against inflammation.

Objective: To identify the effects of LC ω-3 PUFAs on reducing the levels of inflammatory markers on hypertensive and/or diabetic obese adults.

Materials and methods: Sixty-four patients, who were hypertensive and/or diabetic obese with high levels of inflammatory markers, from primary healthcare centers of Gaza City, Palestine, enrolled in two groups of an open-label, parallel, randomized, controlled trial for 8 weeks. Thirty-three patients were in the control group, and 31 patients were in the experimental group. The experimental group was treated with a daily dose of 300 mg eicosapentaenoic acid and 200 mg of docosahexaenoic acid.

Results: Treatment with LC ω-3 PUFAs significantly reduced the level of high sensitivity C reactive protein (hs-CRP) [14.78±10.7 to 8.49±6.69 mg/L, p<0.001], fasting blood glucose (FBG) [178.13±58.54 to 157.32±59.77 mg/dL, p=0.024], and triglyceride (TG) [209.23±108.3 to 167.0±79.9 mg/dL, p<0.05] after 8 weeks of treatment, whereas no significant changes appeared in interleukin 6 (IL-6) and total cholesterol (TC). In the control group, significant reduction was detected for FBG [187.15±64.8 to 161.91±37.9 mg/dL, p<0.05] and TG [202.91±107.0 to 183.45±95.82 mg/dL, p<0.05], and no changes for hs-CRP, IL-6, or TC. By comparing the experimental group with the changes of control group at the endpoint, LC ω-3 PUFAs did not reach the clinical significance in treating effectiveness for any of the clinical variables.

Conclusion: LC ω-3 PUFAs have recommended effects on health; the obtained results can improve the role of LC ω-3 PUFAs as a protective factor on inflammation and metabolic dysregulation. The time allowed or the dose used could be insufficient to achieve full treatment affectivity.

Keywords: DHA; EPA; diabetes; hypertension; inflammation; obesity; omega-3 fatty acids.


Fig. 1
Fig. 1
Consolidated Standards of Reporting Trials (CONSORT) flowchart. BMI, body mass index; DM, diabetes mellitus; HT, hypertension; LC ω-3 PUFAs, long-chain omega-3 polyunsaturated fatty acids; PA, level of physical activity; SD, standard deviation; WC-F, waist circumference – females; WC-M, waist circumference – males.

Similar articles

See all similar articles

Cited by 5 articles


    1. Musaiger AO. Overweight and obesity in the Eastern Mediterranean Region: can we control it? Eastern Mediterr Health J. 2004;10(6):789–93. - PubMed
    1. Abdeen Z, Jildeh C, Dkeideek S, Qasrawi R, Ghannam I, Al-Sabbah H. Overweight and obesity among Palestinian adults: analyses of the anthropometric data from the First National Health and Nutrition Survey (1999–2000) J Obes 2012. 2012 213547, doi: - DOI - PMC - PubMed
    1. El Kishawi R, Soo K, Abed Y, Muda W. Obesity and overweight: prevalence and associated socio demographic factors among mothers in three different areas in the Gaza Strip-Palestine: a cross-sectional study. BMC Obes. 2014;1 7, doi: - PMC - PubMed
    1. Jamee A, Abed Y, Abutawila H. Risk factors of metabolic syndrome among clinic patients in Gaza - Palestine. Am J Cardiovasc Dis. 2013;1(1):20–4. doi: - DOI
    1. Abukhdeir HF, Caplan LS, Reese L, Alema-Mensah E. Factors affecting the prevalence of chronic diseases in Palestinian people: an analysis of data from the Palestinian Central Bureau of Statistics. East Mediterr Health J. 2013;19(4):307–13. - PMC - PubMed